Serotonin 5-HT Morris water maze Cincinnati water maze Corticosterone Brain development a b s t r a c t Rationale: Neonatal rat methamphetamine (MA) exposure has been shown to cause long-term behavioral impairments similar to some of those observed following neonatal stress. The mechanism by which MA induces impairments is unknown but may be related to early increases in corticosterone release. We previously developed a method to attenuate MA-induced corticosterone release using adrenal autotransplantation (ADXA) in neonatal rats. This exposure period corresponds to the second-half of human pregnancy. Objective: To determine whether inhibition of neonatal MA-induced increases in corticosterone attenuates the long-term behavioral deficits associated with early MA treatment. Results: ADXA successfully attenuated MA-induced plasma corticosterone increases by ∼50% during treatment (P11-20) but did not attenuate the long-term behavioral effects of MA treatment. MA-treated rats, regardless of surgery, showed increased errors and latencies in the Cincinnati water maze test of egocentric learning and increased latency, path length, and cumulative distance in three phases of Morris water maze spatial learning and reference memory. MA-treated offspring were hypoactive, had subtle reductions in anxiety in the elevated zero maze but not in the light-dark test. ADXA had no effect on MA-induced long-term 5-HT reductions in the neostriatum or entorhinal cortex or on 5-HIAA reductions in the hippocampus. Conclusions: Fifty percent attenuation of neonatal MA-induced elevations in corticosterone does not alter the long-term egocentric or allocentric learning deficits or other behavioral effects of neonatal MA exposure. Because the ADXA effect was partial, the data cannot rule out the possibility that a more complete block of MA-induced corticosterone release might not prevent later cognitive deficits.
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Introduction
Methamphetamine (MA) abuse has become a worldwide problem (Johnston et al., 2008a,b; Srisurapanont et al., 2001) . MA is abused primarily by adolescents and young adults (Johnston et al., 2008a,b) . Some percentage of female users will become pregnant.
Abbreviations: MA, methamphetamine; CORT, corticosterone; ADXA, adrenal autotransplantation; DA, dopamine; 5-HT, serotonin.
* Approximately 40% of pregnant MA users continue to use throughout pregnancy (Smith et al., 2003) . One out of every 4 pregnant women seeking drug treatment in the U.S. reports MA as their primary drug of abuse (Terplan et al., 2009) . Since MA readily crosses the placenta (Burchfield et al., 1991; Garcia-Bournissen et al., 2007) , fetal exposure in such cases is inevitable.
A limited number of human prenatal MA studies exist. Findings include reduced birth weight, length, and head circumference and higher rates of placental and intraventricular hemorrhage and anemia (Chomchai et al., 2004; Dixon, 1989; Dixon and Bejar, 1989; Little et al., 1988; Oro and Dixon, 1987; Smith et al., 2008) . Additionally, increased agitation, vomiting, temperature instability, and rapid respiration have been noted (Chomchai et al., 2004) . Magnetic resonance imaging studies report that exposed children have smaller volumes of the hippocampus, putamen, and globus pallidus, and reduced attention, visual motor integration, psychomotor speed, and spatial and verbal memory (Chang et al. 
